Patents by Inventor ELISABETE NASCIMENTO

ELISABETE NASCIMENTO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
    Publication number: 20240124549
    Abstract: Fusion proteins include an extracellular domain of PD1 protein (programmed cell death protein-1) and/or an extracellular domain of PD-L1 protein (programmed cell death-ligand 1 protein (CD274 or B7-H1)). Portions of the extracellular domains are expressed in specific configurations and purified as protein, which are used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. A method is for determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient when the patient has undergone at least one dose of immunotherapy.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 18, 2024
    Inventors: Jody BERRY, Elizabeth BOOTH, Joyee ANTONY GEORGE, Elisabete NASCIMENTO, Daniel NAGORE CASAS
  • Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
    Patent number: 11919938
    Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: March 5, 2024
    Assignee: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: Jody Berry, Elizabeth Antony Booth, Joyee Antony George, Elisabete Nascimento, Daniel Nagore Casas
  • FUSION PROTEINS COMPRISING SARS-COV-2 NUCLEOCAPSID DOMAINS
    Publication number: 20230303629
    Abstract: A fusion protein includes a SARS-CoV-2 nucleocapsid N-terminal domain and/or a SARS-CoV-2 nucleocapsid C-terminal domain, wherein the fusion protein lacks the SARS-CoV-2 nucleocapsid aggregation domain.
    Type: Application
    Filed: August 17, 2021
    Publication date: September 28, 2023
    Inventors: EFRAIN CEH PAVIA, ELISABETE NASCIMENTO, ELIZABETH A. BOOTH, ZEBULON LAPOINT, CHARLES HOLZ, TRISTAN WASLEY, JODY MELTON WITT
  • IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
    Publication number: 20200299353
    Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
    Type: Application
    Filed: November 29, 2018
    Publication date: September 24, 2020
    Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: JODY BERRY, ELIZABETH Antony BOOTH, JOYEE ANTONY GEORGE, ELISABETE NASCIMENTO, DANIEL NAGORE CASAS